Question 1

What is zilucoplan and what condition does it treat?

Accepted Answer

Zilucoplan (brand name Zilbrysq) is a macrocyclic peptide complement C5 inhibitor approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Myasthenia gravis is a chronic autoimmune neuromuscular disorder in which antibodies attack the acetylcholine receptors at the neuromuscular junction, causing fatigable muscle weakness that can affect eye muscles, facial muscles, limbs, and in severe cases, respiratory muscles. Zilucoplan blocks the terminal complement cascade that is pathologically activated by these autoantibodies, reducing destruction of the neuromuscular junction and improving muscle function.

Question 2

How does zilucoplan differ from eculizumab and ravulizumab?

Accepted Answer

Zilucoplan, eculizumab, and ravulizumab all inhibit complement C5, but they differ fundamentally in their molecular nature, route of administration, and dosing convenience. Eculizumab and ravulizumab are monoclonal antibodies (large ~148 kDa proteins) requiring intravenous infusion in a clinical setting — eculizumab every 2 weeks and ravulizumab every 8 weeks. Zilucoplan is a small macrocyclic peptide (~3,500 Da) that can be self-administered via daily subcutaneous injection at home, offering significantly greater convenience and patient autonomy. Additionally, zilucoplan binds C5 at a distinct epitope from the antibody-based inhibitors, which has implications for patients with certain C5 polymorphisms (such as the R885H variant common in East Asian populations) that can reduce eculizumab efficacy but may not affect zilucoplan binding.

Question 3

Why is meningococcal vaccination required before starting zilucoplan?

Accepted Answer

Terminal complement pathway activity (C5b through C9, culminating in the membrane attack complex) is essential for immune defense against Neisseria meningitidis, the bacterium causing meningococcal meningitis and septicemia. Individuals with genetic deficiencies in terminal complement components have a dramatically increased risk (1,000–10,000 fold) of invasive meningococcal disease. Because zilucoplan blocks C5 cleavage and MAC formation, treated patients are similarly vulnerable. FDA labeling requires vaccination with meningococcal vaccines (covering serogroups A, C, W, Y, and B) at least 2 weeks prior to initiating treatment to allow adequate antibody development. Patients must also be monitored for early signs of meningococcal infection throughout treatment, and may require prophylactic antibiotics in certain circumstances.

Question 4

What were the results of the RAISE clinical trial?

Accepted Answer

The RAISE trial was a pivotal Phase III, randomized, double-blind, placebo-controlled study that enrolled 174 adults with anti-AChR antibody-positive generalized myasthenia gravis. Patients received either weight-based zilucoplan (approximately 0.3 mg/kg) or placebo by daily subcutaneous injection for 12 weeks, with background stable immunosuppressive therapy allowed. The primary endpoint was the change from baseline in the MG-ADL score at Week 12, where zilucoplan demonstrated a statistically significant improvement (−3.37 vs. −2.30; treatment difference −1.07; p=0.0382). Secondary endpoints also showed significant improvements: QMG score (−4.39 vs. −2.30), MG Composite score, and MG-QoL15r. Rapid onset of benefit was observed, with some endpoints showing separation from placebo by Week 1.

Question 5

What are the most common side effects of zilucoplan?

Accepted Answer

In clinical trials, the most commonly reported adverse reactions with zilucoplan were injection site reactions (including erythema, pain, pruritus, and swelling, occurring in approximately 18% of patients), upper respiratory tract infections (12%), and diarrhea (9%). Most injection site reactions were mild and did not lead to treatment discontinuation. The most serious potential risk is meningococcal infection, which is mitigated by mandatory pre-treatment vaccination and ongoing clinical monitoring. Other potential concerns include increased susceptibility to infections with other encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae type b) due to impaired terminal complement function, though the clinical significance of this risk appears to be lower than for meningococcal species.

Question 6

How is zilucoplan administered in practice?

Accepted Answer

Zilucoplan is self-administered as a once-daily subcutaneous injection using a pre-filled syringe. The dose is weight-based: 16.6 mg for patients under 56 kg, 23.0 mg for patients between 56 and 77 kg, and 32.4 mg for patients over 77 kg (corresponding to approximately 0.3 mg/kg). Injection sites include the abdomen, thigh, or upper arm, with rotation of sites recommended to minimize injection site reactions. Patients and caregivers receive training on proper injection technique before initiating self-administration. The pre-filled syringes can be stored at room temperature for up to 3 months (single excursion from refrigeration), making the product convenient for travel and daily use without requiring cold chain access at all times.

Question 7

What is the complement system and how does it contribute to myasthenia gravis?

Accepted Answer

The complement system is a cascade of over 30 plasma and membrane-bound proteins that form a key effector arm of innate immunity. It can be activated through three pathways: classical (antibody-mediated), lectin, and alternative. In anti-AChR antibody-positive myasthenia gravis, IgG1 and IgG3 autoantibodies bind to acetylcholine receptors at the neuromuscular junction and activate the classical complement pathway by engaging C1q. This triggers a proteolytic cascade through C2, C3, and C4, ultimately generating C5 convertases that cleave C5 into C5a (an inflammatory mediator) and C5b (which initiates MAC assembly). The MAC (C5b-9) forms pores in the postsynaptic membrane, causing focal lysis, loss of junctional folds, and reduced AChR density — all of which impair neuromuscular transmission and produce the characteristic fatigable weakness of myasthenia gravis.

Question 8

Can zilucoplan be used in seronegative or MuSK-positive myasthenia gravis?

Accepted Answer

Zilucoplan is currently FDA-approved only for anti-AChR antibody-positive generalized myasthenia gravis. It has not demonstrated efficacy in, and is not indicated for, anti-MuSK antibody-positive gMG or seronegative gMG. This restriction reflects the pathophysiology of these subtypes: MuSK antibodies are predominantly IgG4, which does not efficiently activate complement, so complement inhibition would not address the primary disease mechanism. Similarly, the pathogenic mechanisms in seronegative gMG are incompletely understood and may not be complement-dependent. Clinical trials specifically enrolled and studied anti-AChR antibody-positive patients, and the therapeutic rationale is strongest for this subset where complement-mediated destruction of the neuromuscular junction is well-established.

Question 9

What is a macrocyclic peptide and why is it advantageous?

Accepted Answer

A macrocyclic peptide is a peptide in which the backbone or side chains are connected by a chemical bond to form a ring (cyclic) structure. This cyclization confers several advantages over linear peptides: increased resistance to proteolytic degradation (improving metabolic stability and extending half-life), constrained conformation that can enhance binding affinity and selectivity for the target protein, improved cell permeability in some cases, and reduced conformational flexibility that lowers the entropic cost of binding. Zilucoplan's macrocyclic structure, combined with PEG conjugation, gives it a half-life of approximately 7.6 days — remarkably long for a peptide — enabling once-daily dosing and sustained C5 inhibition. The small size (~3,500 Da vs. ~148,000 Da for antibodies) enables subcutaneous self-administration with small injection volumes.

Question 10

What happens if zilucoplan treatment is interrupted or discontinued?

Accepted Answer

If zilucoplan is discontinued or interrupted, complement C5 activity will gradually recover as the drug is cleared from the body. Given the approximately 7.6-day half-life, near-complete recovery of complement function would be expected within 4–6 weeks after the last dose. During this period, patients may experience a return or worsening of myasthenia gravis symptoms as complement-mediated neuromuscular junction damage resumes, potentially including myasthenic crisis in severe cases. Patients should not discontinue zilucoplan without medical supervision, and clinicians should have a plan for alternative immunotherapy if discontinuation is necessary. The risk of rebound complement activation and symptom flare should be monitored closely, particularly in the first 2–4 weeks after stopping treatment.

Question 11

Zilucoplan targets complement C5 — how does that differ from the C3 inhibitor pegcetacoplan?

Accepted Answer

Both are complement inhibitors, but they act at different levels of the cascade. Zilucoplan is a macrocyclic peptide that blocks C5, the terminal step that forms the membrane-attack complex, and it is used in generalized myasthenia gravis. Pegcetacoplan blocks C3, a more central and upstream hub, and is used in paroxysmal nocturnal hemoglobinuria and geographic atrophy. Blocking C3 controls both the terminal pathway and the earlier C3-fragment 'tagging' of cells that C5 inhibition leaves untouched — a distinction that matters in PNH, where extravascular red-cell destruction can persist on C5 therapy. Both classes raise the risk of encapsulated-bacterial infection, so meningococcal vaccination is required before starting either.

Origin / Manufacturer	Synthetic macrocyclic peptide with PEG conjugation
Regulatory Status	FDA-Approved (October 2023)cGMP Manufactured
Active Components	Zilucoplan sodiumSodium phosphate monobasic monohydrateSodium phosphate dibasic anhydrousSodium chlorideWater for injection
Storage	Store refrigerated at 2–8°C (36–46°F). May be stored at room temperature up to 30°C (86°F) for a single period of up to 3 months in the original carton. Do not freeze.
Shelf Life	24 months refrigerated; 3 months at room temperature (single excursion)
Form Factor	Pre-filled syringe for subcutaneous injection (16.6 mg/0.416 mL, 23.0 mg/0.574 mL, 32.4 mg/0.810 mL)

Zilucoplan

Specifications

Frequently Asked Questions

Related Peptides

KPV

LL-37

Thymosin α1

Thymosin Beta-4